Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Boostrix booster immunogenicity and reactogenicity in healthy adults previously boosted in dTpa-029
2009-016012-21Phase 4Completed
- Sponsor
- GSK
- Start
- Apr 2010
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of acellular pertussis vaccine in diphtheria, Tetanus and pertussis (2 arms), sponsored by GSK. Primary endpoints: Immune persistence at 8.5 and 10 years after previous booster, Safety and reactogenicity of booster vaccination and 1 more. Started Apr 2010; status: completed.
02
Drugs
acellular pertussis vaccine
03
Conditions
diphtheriaTetanuspertussis
Beyond the preview
Go deeper on 2009-016012-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016012-21.